<DOC>
	<DOCNO>NCT01705379</DOCNO>
	<brief_summary>A multicenter , single arm , postmarketing surveillance study . This study postlicensure requirement Philippine Food Drug Administration ( FDA ) provide continue safety evaluation MenACWY-CRM Philippine individual 2 year age old , receive MenACWY-CRM vaccination accord routine clinical practice prescribe information .</brief_summary>
	<brief_title>Safety One Dose Meningococcal ACWY Conjugate Vaccine Subjects 2 Years Age Older</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Individuals eligible enrolment study : 1. gender , age 2 old , whom/whose parent legally acceptable representative nature study describe subject/subject 's parent/legally acceptable representative provide write informed consent . 2. investigator believe subject and/or parent/legal representative comply requirement protocol . 3. good health determine clinical judgment investigator . Individuals eligible enrol study : 1. unwilling unable give write informed consent assent participate study . 2. perceive unreliable unavailable duration study period . 3. previously immunize meningococcal vaccine vaccine contain meningococcal antigen ( ) ( licensed investigational ) . 4. receive investigational nonregistered product ( drug vaccine ) within 30 day prior enrolment expect receive investigational drug vaccine prior completion study . 5. receive plan receive vaccine ( routine childhood vaccine ) within 30 day administration study vaccine . ( Exception : Influenza vaccine may administer 15 day prior study vaccination least 15 day study vaccination ) 6. behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study . 7. pregnant breast feeding ( female subject appropriate age ) plan become pregnant course study . 8. serious acute , chronic progressive disease ( e.g. , history neoplasm , cancer , diabetes , cardiac disease , autoimmune disease , HIV infection AIDS , blood dyscrasia , sign cardiac renal failure severe malnutrition ) , epilepsy progressive neurological disease history GuillainBarre syndrome . 9. history anaphylaxis , serious vaccine reaction , allergy vaccine component . 10. known bleed diathesis , condition may associate prolonged bleeding time . 11. include study personnel close family member personnel conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neisseria meningitidis , conjugate vaccine , phase IV clinical trial</keyword>
</DOC>